Article Text

Download PDFPDF

Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors
  1. Öystein Rekdal1,
  2. Takahiro Yamazaki2,
  3. Baldur Sveinbjornsson3,
  4. Andrew Saunders4 and
  5. Laurence Zitvogel5
  1. Aff1 grid.458209.20000 0004 0495 1516Lytix Biopharma Oslo Norway
  2. Aff2 grid.14925.3b0000000122849388Gustave Roussy Cancer Campus Villejuif France
  3. Aff3 grid.10919.300000000122595234University of Tromsö Tromso Norway
  4. Aff4 Lytixbiopharma Oslo Norway
  5. Aff5 grid.14925.3b0000000122849388Gustave Roussy Cancer Campus Villejuif France

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Host defense peptides (HDPs) are naturally occurring molecules found in most eukaryotic species, in which they play a significant role in the first line of defense against pathogens. Several HDPs have shown to possess anticancer activity. Structure-anti-cancer activity relationship studies on the HDP bovine lactoferricin has resulted in the design of a short oncolytic 9-mer peptide, LTX-315. Mode of action studies indicate that LTX-315 induces release of tumour antigens and potent DAMPS by distortion of intracellular organelles in cancer cells. Animal studies have demonstrated that intratumoural (i.t.) treatment of several different types of syngeneic murine tumours with LTX-315 resulted in complete tumor regression and tumor specific immune responses. In the present study, we examined the potential synergistic effects of using LTX-315 in combination with anti-PD1 or anti-CTLA4 blockade.


C57BL/6 mice with MCA205 sarcomas were first treated i.p. with either anti-PD1 Ab or anti-CTLA4 Ab followed by intra-tumoural administration of LTX-315.


Intratumoural (i.t.) administration of LTX-315 resulted in a synergistic antitumour effect when combined with i.p. administration of anti-PD1 or anti-CTLA4 compared to the effect of either the immune checkpoint inhibitors or LTX-315 alone. A synergistic effect was also achieved against distant non-treated lesions with local administration of anti-CTLA4 Ab (s.c.) and LTX-315 (i.t.) in combination.


Our results demonstrate that LTX-315 in combination with anti-CTLA4 or anti-PD1 results in a synergistic antitumour effect in vivo. Thus, a combination therapy with the oncolytic peptide LTX-315 that mounts specific T cell responses against released tumour antigens and immune checkpoint inhibitors that can augment the tumour specific T cell responses represent a promising combination strategy in future cancer therapy. One Phase I study with LTX-315 is completed and a 2nd is ongoing. Combination studies together with immune checkpoint inhibitors are planned.